We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Medical experts who’ve studied the experimental treatment program, however, say there’s no evidence to support Trump’s claims ...

Prilenia Therapeutics B.V., a biopharmaceutical company focused on developing novel therapeutics to treat neurodegenerative ...

Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...

November is Alzheimer's Awareness Month, and if you have a loved one in the beginning stages of the disease, a local clinical ...

Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the CTAD 2024 conference. Read why ...

Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in ...

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...